John B Henneman Iii is Director of Anika Therapeutics, Inc.. Currently has a direct ownership of 35,707 shares of ANIK, which is worth approximately $605,947. The most recent transaction as insider was on Jul 09, 2024, when has been sold 5,771 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 35.7K
0% 3M change
19.28% 12M change
Total Value Held $605,947

JOHN B HENNEMAN III Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 09 2024
BUY
Grant, award, or other acquisition
-
5,771 Added 13.91%
35,707 Common Stock
Jun 14 2023
BUY
Grant, award, or other acquisition
-
6,500 Added 17.84%
29,936 Common Stock
Jun 08 2022
BUY
Grant, award, or other acquisition
-
7,954 Added 25.34%
23,436 Common Stock
Jun 16 2021
BUY
Grant, award, or other acquisition
-
4,172 Added 21.23%
15,482 Common Stock
May 18 2021
BUY
Open market or private purchase
$85,720 $42.86 p/Share
2,000 Added 15.03%
11,310 Common Stock

Also insider at

SPNE
SeaSpine Holdings Corp Healthcare
APRE
Aprea Therapeutics, Inc. Healthcare
RCM
R1 RCM Inc. Healthcare
OFIX
Orthofix Medical Inc. Healthcare
JBH

John B Henneman Iii

Director
Boston, MA

Track Institutional and Insider Activities on ANIK

Follow Anika Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ANIK shares.

Notify only if

Insider Trading

Get notified when an Anika Therapeutics, Inc. insider buys or sells ANIK shares.

Notify only if

News

Receive news related to Anika Therapeutics, Inc.

Track Activities on ANIK